Return to The AAPP Perspective issue main page.< Previous Article  Next Article >

CPNP is pleased to announce the development of 19 hours of recorded educational programming on opioid use disorder (OUD) and treatment. These activities are designed to meet the educational needs of pharmacists and other health care professionals who are able to contribute to managing the medication of patients with OUD.

Although access to single activities within the full educational program will be allowed, those completing all of the modules should be able to:

  1. Identify individuals at risk for opioid overdose and develop an appropriate treatment plan
  2. Screen and refer patients with opioid use disorder for treatment
  3. Develop an evidence-based treatment plan for medication assisted treatment
  4. Describe and implement harm reduction strategies for patients with opioid use disorder
  5. Assess, initiate, and modify opioid use disorder treatment planning using evidence-based recommendations
  6. Discuss the psychiatric and medical co-morbidities associated with opioid use disorder
  7. Apply regulatory and best practices to optimize care and safety for patients with opioid use disorder

A full listing of educational sessions and learning objectives under development is available here. A snapshot of the learning activities under development is provided below.

  • Common Yet Different Threads: Managing Pain in the Setting of Opioid Use Disorder 
    Michele Matthews, PharmD, BCACP, CPE, FASHP, MCPHS University
  • Comorbid Disorders
    Troy Moore, PharmD, MS, BCPP, Eastern Colorado Health Care System/Rocky Mountain Regional VA Medical Center
  • Diversion
    Michael O'Neil, PharmD, South College School of Pharmacy
  • Harm Reduction
    Michelle Geier, PharmD, BCPP, San Francisco Department of Public Health
  • Health Care Providers in Recovery
    Brian Fingerson, BS Pharm, RPh, FAPhA, KY Professionals Recovery Network - KYPRN
  • Inpatient Management: Regulatory, Detox, Starting Treatment in the Emergency Room (Acute Care Management)
    Curtis Geier, PharmD, BCCCP, San Francisco General Hospital and Trauma Center
  • Interprofessional Communication Among Prescribers and Pharmacists who Care for Patients with Opioid Use Disorder (OUD): Barriers and Solutions
    Nicholas Hagemeier, PharmD, PhD, East Tennessee State University
  • Interprofessional Excellence: Integrating Pharmacists into the Team for Pharmacotherapy of OUD
    Bethany DiPaula, PharmD, BCPP, University of Maryland; Sarah Melton, PharmD, BCPP, BCACP, FASCP, Gatton College of Pharmacy; Troy Moore, PharmD, MS, BCPP, Eastern Colorado Health Care System/Rocky Mountain Regional VA Medical Center
  • Naloxone Education and Distribution: Pharmacists on the Frontline in Preventing Opioid Overdose
    Sarah Melton, PharmD, BCPP, BCACP, FASCP, Gatton College of Pharmacy
  • Neonatal, Pregnancy, Lactation
    Kristin Harter, PharmD, Zuckerberg San Francisco General
  • Pharmacotherapy for OUD: Levels of Care and Types of Service 
    Cassandra Davis, PharmD, BCPS, BCPP, Orlando VA Medical Center
  • Screening and Referral
    Sarah Melton, PharmD, BCPP, BCACP, FASCP, Gatton College of Pharmacy
  • Setting up an OUD Practice in the Community or Retail Pharmacy Setting
    Morgan Miller, PharmD, Alps Specialty Pharmacy
  • Special Considerations for Incarcerated Patients
    Jennifer Nelson, PharmD, BCPP, Parkland Health & Hospital System
  • The Opioid Epidemic – History, Stigma, Progress, and Pharmacotherapy
    Julie Kmiec, DO, Western Psychiatric Hospital of UPMC
  • Treatment of OUD in Children and Adolescents
    Scott Hadland, MD, MPH, MS, Boston Medical Center / Boston University School of Medicine
  • Treatment of OUD in Older Adults
    Ericka Crouse, PharmD, BCPP, BCGP, BCGP, FASHP, FASCP, VCU School of Pharmacy
  • Urine Drug Screens
    Karen Moeller, PharmD, BCPP, University of Kansas

Don’t forget to check out all of the other valuable CPNP substance use disorder resources as follows:

Toolkits

Courses

Educational grant support for the Opioid Use Disorder and Treatment educational program is provided by Alkermes

Return to The AAPP Perspective issue main page.< Previous Article  Next Article >